Barclays Maintains an 'Equalweight' on PharMerica (PMC); December Quarter Review - After the Call
Tweet Send to a Friend
Barclays maintains an 'Equalweight' on PharMerica (NYSE: PMC), PT $13.
Barclays analyst says, "Last week, PMC reported better-than-expected 4Q10 results ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Barclays analyst says, "Last week, PMC reported better-than-expected 4Q10 results ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
